CMS Pays AI MORE Than Human Interpretation for Diabetic Retinopathy Screening — CPT 92229 = $43.67 (2025) vs 92228 = $29.14
CMS deliberately reimburses autonomous AI more than human interpretation for diabetic retinopathy screening. CPT 92229 (autonomous AI imaging) = $40.94 (2024) → $43.67 (2025); CPT 92228 (MD interpretation) = $29.14; CPT 92227 (staff review) = $17.35.
The price differential is intentional policy: CMS uses reimbursement to drive autonomous AI adoption in primary care settings — the policy tailwind for FQHCs is real. Combined with $43.67 reimbursement vs ~$15-25K refurbished Topcon NW400 fundus camera, AI DR screening pays for the equipment within months for any FQHC with a Type 2 diabetes panel.
Plus HEDIS EED quality measure improvement (only 64.8% of US diabetics get annual exam vs HP2030 70.3% target). The single most ROI-positive vision technology FQHCs are not adopting at scale.
Primary source
CMS / EyenukFQHC Talent. (2025, January 1). CMS Pays AI MORE Than Human Interpretation for Diabetic Retinopathy Screening — CPT 92229 = $43.67 (2025) vs 92228 = $29.14. Primary source: CMS / Eyenuk. Retrieved June 15, 2026, from https://www.fqhctalent.com/intel/cms-cpt-92229-autonomous-ai-reimbursement-2025
More in Funding & Budget
Dec 31
CalAIM Section 1115 Waiver Expires December 2026 — $1.2B/Year at Stake
Jun 11
California's June 11 Budget Deal Delays the ~$1B FQHC Reimbursement Cut by 12 Months — a $1.034 Billion General-Fund Reprieve for Health Centers, Plus the MCO Tax and Softened Immigrant Cuts
Jun 10
California Breaks Ground on a New Modesto Youth Behavioral-Health Center — a >$5M BHCIP Award and a Rare Central Valley Infrastructure Win
Jun 10
The $50B rural health fund is now real money with real deadlines: Florida June 17, Alaska June 22, Indiana July 1, Tennessee July 6-20 — and FQHCs must compete for every dollar